 Home > Chemicals Industry > China Chemical > The monoclonal antibody industry is ushering in a period of vigorous development, and domestic equipment needs to accelerate the substitution of imports

The monoclonal antibody industry is ushering in a period of vigorous development, and domestic equipment needs to accelerate the substitution of imports

 Last Update: 2022-03-10
 Source: Internet
 Author: User

Tags

salicylic acid 10

british pharmaceutical companies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

[ Focus on Chemical Machinery Equipment Network ] Monoclonal antibodies are highly uniform antibodies that are produced by a single B cell clone and only target a specific epitope.
They have clear targeting, high safety and effectiveness, and can be used for Clinical treatments in key disease areas such as cancer and autoimmune system diseases provide better choices and are therefore favored by the market.
The data shows that the monoclonal antibody market segment accounted for 55.
3% of the biological drug market in 2018, but the Chinese monoclonal antibody market only accounted for 6.
1% of the total biological drug market, and the domestic monoclonal antibody product category was small and the coverage rate was low.
In the future, as more and more monoclonal antibody drugs enter medical insurance and the introduction of immunotherapy products, the industry expects that China's monoclonal antibody market will usher in greater room for growth.
In this context, related equipment companies may usher in opportunities.

Chemical machinery and equipment network hotspots pay attention to chemical machinery and equipment

The monoclonal antibody industry ushered in a period of vigorous development

It is understood that due to the high technical barriers of monoclonal antibodies, the difficulty of development and production, and the high cost of immunotherapy, the monoclonal antibody market in my country has been monopolized by foreign companies in the past, and the domestic monoclonal antibody drug market is in China’s overall pharmaceutical market.
The proportion is very small.

　　In February 2017, the new version of my country's medical insurance catalog was released.
Six monoclonal antibody drugs with definite curative effects, few side effects, and urgent demand but relatively high prices successfully entered the medical insurance category B after price negotiations.
Later, in the second and third rounds of national medical insurance price negotiations, one and six monoclonal antibody drugs appeared in the medical insurance catalog respectively.

　　These monoclonal antibody drugs included in medical insurance can reduce the burden of patients' drug costs on the one hand and benefit more patients with clinical needs, and on the other hand, it is also conducive to the realization of higher volumes of products.
Taking Sintilizumab, which entered medical insurance in 2019, as an example, the company announcement shows that Sintilizumab was approved for listing in March 2019, and its sales have increased quarter by quarter.
In 2019, its annual sales were 1.
016 billion, and the figure in 2020Q3 has exceeded 600 million.
It is expected that sales in 2020 will exceed the 2 billion mark.

　　From the domestic situation, there are currently four domestically produced PD-1 monoclonal antibodies on the market, and the total sales in the first half of the year reached nearly 4 billion yuan.
In addition, some new targets such as CD47 and OX40 have also been developed by pharmaceutical companies.
For example, not long ago, Tianjing Biological and AbbVie reached a strategic cooperation on the development and commercialization of the company’s research CD47 monoclonal antibody TJC4; in addition, the process of Innovent’s OX40 monoclonal antibody is also accelerating, and it has now entered phase I clinical trials .

　　With the intensification of aging and the continuous upgrading of consumption, the domestic demand for biological drugs will continue to grow.
Coupled with the continuous expansion of medical insurance coverage and listed products, the industry expects that my country's monoclonal antibody market will usher in a period of rapid development.

　　Opportunities and challenges coexist for related equipment companies

　　While the monoclonal antibody industry is ushering in opportunities, relevant monoclonal antibody equipment companies will also usher in good opportunities.
At present, some domestically-produced companies have indicated that they can provide services such as equipment and overall solutions for the monoclonal antibody industry.
For example, Tofflon recently stated on the interactive platform that it can currently provide services for monoclonal antibodies, recombinant proteins, blood products, and human/veterinary vaccines.
It can not only provide biomedical customers with process equipment, but also provide them with integrated services.
Solutions (process + equipment + engineering), biological process integration and other services.
In August this year, Tofflon also replied on the interactive platform that the company's prefilling production line can be used for the production and packaging of various sterile products such as vaccines, monoclonal antibodies, small molecule heparins, insulin, and hyaluronic acid.

　　It is worth mentioning that the current equipment used in this industry is almost entirely dependent on imports, while domestic monoclonal antibody equipment still has a clear gap in comparison.
It requires enterprises to increase R&D investment, keep innovating, and gradually break the import monopoly.

　　"Our goal for ourselves is to take 5-10 years to gradually replace imported products with our domestic equipment.
" At the 2020 Shanghai Bio-Fermentation Exhibition that ended not long ago, some biological equipment suppliers expressed their intentions.
The determination to open up markets such as monoclonal antibodies.

　　Original title: The monoclonal antibody industry ushered in a period of vigorous development, and domestic equipment needs to accelerate the substitution of imports

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.